surprise you are still here after you sold several times and didnt like the stock.. who cares if you post you sold the stock when you didnt post when you bought.....sounds like a one way trade.....no need posting here
Sentiment: Strong Buy
as indicated on Fidelity trading site I use''stocastics still in buy mode...http://finance.yahoo.com/q/ta?t=1y&l=on&z=l&q=b&p=m50%2Cm100%2Cm200%2Cv&a=m26-12-9%2Cr14%2Css&c=&s=ipci&ql=1
There's been a very significant rally," said Rick Meckler, president of investment firm LibertyView Capital Management in Jersey City, New Jersey. "If you need an excuse to sell, this is a good one."
Russian stocks and bonds
skeptical about the posts on Fly on the Wall....maybe someone was trying to run up the stock which them did until close to the close when maybe sold out not making any profil...just strange action and the close alot higher than the previous trade..
Blackstone’s biggest gain was on paper. Hotel chain Hilton Worldwide Holdings Inc. (HLT)’s initial public offering in December has yielded a more than $10 billion profit, which will be unrealized until Blackstone begins selling shares.Mr. Schwarzman, who has yet to sell any Blackstone shares since the firm's initial public offering, holds about 22% of the firm's stock......“We’re in a really marvelous position and I don’t worry about growth -- it’s just coming at us,” Schwarzman said in a television interview yesterday. “I worry about delivering great investment products for investors. And if you do that all the time and you do it at scale, good things will happen to you.”
JP Morgan call on Freescale adds confusion 02/28 10:47 AM
By Natalie Harrison and Lynn Adler
NEW YORK, Feb 28 (IFR/RLPC) - JP Morgan CEO Jamie Dimon delivered a confident message at the bank's global high-yield conference this week, telling attendees it would be no more cautious than any other Wall Street bank when it comes to lending, according to investors present at the event.
But the bank's decision not to extend a revolving credit facility for Freescale Semiconductor (FSL:$22.83,00$-0.12,00-0.52%) earlier this month, a move confirmed by two market sources, appeared to send a very different message to the market.
It was deemed an unusual decision mainly because revolvers are usually private deals with relationship banks. By not extending the maturity of the revolver, JP Morgan passed up fees, which some bankers said did not make sense as it still had to honor the existing facility.
JP Morgan declined to comment.
The revolver got done - and at a larger size. Citigroup, Goldman Sachs, Credit Suisse, Deutsche Bank, Barclays and Morgan Stanley all committed to the deal, which was increased by up to USD50m to a total of up to USD450m.
The decision demonstrates how carefully banks are scrutinizing which loans, and how many, they will commit to - and there is clearly a ripple effect from the leveraged lending guidance issued about a year ago by regulators.
Some reckon JP Morgan made the correct bet on Freescale, which was taken private by sponsors Blackstone, Carlyle, TPG and Permira in 2006 in one of the biggest leveraged buyouts of all time.
Although the company listed five years later, its leverage remains high.
"You could say JP Morgan has been smart," said one senior banker at a rival bank. "Maybe it made a judgment and thought the company was not a big client, and therefore, not worth doing. The bank's the largest underwriter of leveraged loans in the market, so this is only natural."
Freescale and its private equity owners were either not immediately available or declined to comment.
SUBSTANDARD REPORT CARD
The rationale behind JP Morgan's decision, the sources said, was that the loan could have been considered "substandard" - one of the definitions that regulators have applied to "criticized" or "non-pass" loans under their guidelines.
Another category - "special mention" - is more common. Considered less risky, those loans are also less likely to rile regulators, bankers said.
"It's a bit like a report card. If you're going to have bad marks, you'd rather have more Bs than Cs," said the banker. "The Freescale revolver, a C grade, was substandard already."
A loan may be criticized if companies are not able to amortize or repay all of their senior debt from free cashflow or half of their total debt in five to seven years. Leverage levels exceeding six times debt to Ebitda after asset sales are also viewed as problematic.
According to Moody's latest report on Freescale, even after it pays down debt with proceeds of a recent share offering, adjusted debt to Ebitda will still remain in the low seven times range.
The guidelines aim to prevent a return to reckless underwriting practices, but until recently the market believed regulators would be more focused on new leveraged buyouts. In fact, the implications of the greater scrutiny are far wider than that.
"The guidance does capture refinancing, though not necessarily an amendment," said Tess Virmani, assistant general counsel at the Loan Syndications and Trading Association.
The Federal Reserve, the FDIC and the Office of the Comptroller were either not immediately available or declined to comment.
Even so, some argued JP Morgan was being too conservative, and said its decision was more about the bank wanting to be seen to be toeing the line, and a desire to keep out of the headlines after paying a USD13bn fine last year to settle multiple government claims over dealings in mortgage securities.
"When he was asked at the conference whether JP Morgan would react differently because of its recent issues, Dimon said he expected all banks to behave the same," said one investor who attended the leveraged finance gathering in Miami.
There is, nonetheless, growing annoyance among bankers who are convinced that regulators have not thought through the whole process.
"They have said that they don't want us to stop lending to companies that are in trouble and need financing. But there are lots of grey areas, and it's very frustrating," said the banker.
How this will all play out remains to be seen. The regulators publish report cards on banks' loans in what is known as a Shared National Credits Program to help communicate what are, and what are not, quality loans.
The SNC last year showed criticized and classified assets remained at elevated levels at 10% and 6.2% respectively in 2013. The volume of criticized assets increased 2.4% to USD302bn, but as a percentage of total commitments, the criticized asset rate fell from the year before.
One banker said it would be interesting to see the reaction to fines doled out if banks are too reckless. Others said that fines were unlikely.
"I don't think the punishment will be fines. There are lots of ways for regulators to turn up the heat. Just coming into the bank to meet the risk people, and telling them they are unhappy would be enough to get banks to stop," said a banker.
Get more news on:SYMBOLS: BX, CG, JPM, FSLNEWS TYPE: Top News, Top Stories: Investing, Top Stories: General, Top Stories: Investing (from Reuters), Bonds, Corporate EventsSECTORS: Financials, Commercial Banks, Capital Markets, Industrials, Electrical Equipment, Information Technology, Semiconductors and Semiconductor Equipment
be assure that BX made a lot of money..nice to have confidence in their ability.. otherwise why invest???
February 28, 2014
09:15 EDT QCOR Questcor continues lower as FDA says reviewing Acthar lab test results
Shares of Questcor (QCOR) are down 3.8% in pre-market trading to $64.90 after falling 9% yesterday following Citron Research claiming the company's Acthar drug faces "severe risk" of being pulled from the market by the FDA. Following the Citron report, the FDA stated in an e-mail to Bloomberg that it had received a letter and lab results from an attorney as mentioned by Citron and was reviewing the materials. Questcor's COO Steve Cartt stated in an e-mail to Bloomberg First Word that "each Acthar lot meets FDA-mandated specifications which have not changed over several decades," the news service reported.
Filed pursuant to Rule 424(b)(5)
Registration No. 333-178190
(to Prospectus dated December 22, 2011)
INTELLIPHARMACEUTICS INTERNATIONAL INC.
This Prospectus Supplement supplements certain information in our Prospectus dated December 22, 2011 (the “Prospectus”), as supplemented by our prior Prospectus Supplement dated November 27, 2013 (the “2013 Supplement”) and our prior Prospectus Supplement dated January 17, 2014 (the “2014 Supplement”). This Prospectus Supplement should be read in conjunction with the Prospectus, the 2013 Supplement and the 2014 Supplement, and is qualified by reference thereto, except to the extent that the information herein supersedes the information contained in the Prospectus, the 2013 Supplement and the 2014 Supplement. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, the 2013 Supplement and the 2014 Supplement, including any amendments or supplements thereto.
Through February 26, 2014, we have sold our common shares through Roth Capital Partners, LLC (“Roth”) under the equity distribution agreement we entered into with Roth for an aggregate purchase price of $4,994,014.00. We are filing this Prospectus Supplement because we are now subject to General Instruction I.B.5 of Form F-3, which limits the amounts that we may sell under the Registration Statement of which this Prospectus Supplement and the Prospectus, the 2013 Supplement and the 2014 Supplement are a part. As a result of these limitations and the current public float (or the aggregate market value of the registrant’s outstanding common stock held by non-affiliates) of our common shares, and in accordance with the terms of our equity distribution agreement with Roth, we may currently offer and sell additional common shares having an aggregate offering price of up to $11,855,986 through at-the-market issuances on the NASDAQ or otherwise. However, in the event our public float subsequently equals or exceeds $75,000,000, we may sell additional amounts under the equity distribution agreement and the Registration Statement of which this Prospectus Supplement and the Prospectus, the 2013 Supplement and the 2014 Supplement are a part, as the limitations on sales under General Instruction I.B.5 of Form F-3 would not then apply.
Our common shares are listed for trading on the Toronto Stock Exchange under the symbol “I” and on The NASDAQ Capital Market under the symbol “IPCI”. On February 26, 2014, the closing sale price of the common shares as reported by the Toronto Stock Exchange and The NASDAQ Capital Market was Cdn$4.33 and $3.90, respectively. On February 26, 2014, the aggregate market value of our outstanding common shares held by non-affiliates was $69,110,216, based on our 22,819,711 outstanding common shares, of which 16,653,064 were held by non-affiliates, and a per share price of $4.15, the closing sale price of our common shares on February 13, 2014 (which is the highest closing price in the last 60 days). We have sold or offered securities having an aggregate market value of approximately $9,636,113 pursuant to General Instruction I.B.5 of Form F-3 during the prior twelve calendar month period that ends on and includes the date of this Prospectus Supplement.
Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” beginning on page S-4 of the 2013 Supplement, and under similar headings in the other documents that are incorporated by reference therein (and any amendments thereto), including our most recent annual report on Form 20-F.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
Prospectus Supplement dated February 27, 2014
stocastics showing buy signal and trading above 50 dma of 3.75.. a nice long consoladation menas a nice move on the breaking of the pattern.. which I think will be up.. http://finance.yahoo.com/q/ta?t=1y&l=on&z=l&q=b&p=m50%2Cm100%2Cm200%2Cv&a=m26-12-9%2Cr14%2Css&c=&s=ipci&ql=1
Sentiment: Strong Buy
when it shows 4 it means 400 shares...
seems no ones follows the jerk psucker???COVERAGE REITERATED: Blackstone (BX) reiterated by Argus. Reiterated rating Buy. 02/27 11:27 AM
Get more news on:SYMBOLS: BXNEWS TYPE: Ratings: Upgrades and DowngradesSECTORS: Financials, Capital Markets
Sentiment: Strong Buy